Volume 1079, Issue 1 p. 310-312

Feasibility of a Type 1 Diabetes Primary Prevention Trial Using 2000 IU Vitamin D3 in Infants from the General Population with Increased HLA-Associated Risk

BRANDY A. WICKLOW

BRANDY A. WICKLOW

For the Winnipeg DVD Study Group, Departments of Pediatrics and Child Health and Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0Z2

Search for more papers by this author
SHAYNE P. TABACK

SHAYNE P. TABACK

For the Winnipeg DVD Study Group, Departments of Pediatrics and Child Health and Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0Z2

Search for more papers by this author
First published: 09 November 2006
Citations: 36
Address for correspondence: Dr. Shayne P. Taback, 685 William Avenue, Winnipeg, MB, Canada R3E 0Z2. Voice: 204-787-1222; fax: 204-787-1655.
 e-mail: [email protected]

Abstract

Abstract: Recent epidemiologic, immunologic, and NOD mouse studies suggest that intervention in the vitamin D system may be a successful method to prevent type 1 diabetes. Newborns at increased HLA-associated risk are randomized to receive either 400 or 2000 IU vitamin D3 by 1 month of age. We show that recruitment of babies from the general population for identification of HLA-associated risk status followed by enrollment to a randomized controlled prevention trial is feasible in Canada.